BOULDER, Colo.–(BUSINESS WIRE)—- $BDSX #patientsfirst–Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced the pricing of an underwritten public offering of 30,500,000 shares of its common stock at a price to the public of $1.15 per share, before underwriting discounts and commissions. The gross proceeds to Biodesix from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Biodesix, are
Click here to view original post
News
GHX Awards 15 Providers and Suppliers for Advancing Healthcare and Improving Patient Lives
LOUISVILLE, Colo., May 15, 2024 /PRNewswire/ — Global Healthcare Exchange (GHX) today honored the recipients of its annual GHXcellence Awards at the GHX Summit, held in Austin, Texas. The 15 awards recognize and honor leaders […]
News
A $280M life science facility is coming to Colorado as it gains more interest from biotech developers
While Boulder, CO-area is a popular spot for hikers and college students, the area has also been increasingly attracting life science and biotech development spaces, and the latest project aims to build up the area’s […]
News
Lewis Capaldi’s Tourette’s Diagnosis Shines Light on the Disorder
Last month, Scottish singer and songwriter Lewis Capaldi announced an indefinite break from touring to focus on his health following a Glastonbury Festival performance where his fans joined in when his Tourette’s symptoms took over. […]
